Journal article

Are symptoms of insomnia related to respiratory symptoms? Cross-sectional results from 10 European countries and Australia

Erla Bjornsdottir, Eva Lindberg, Bryndis Benediktsdottir, Thorarinn Gislason, Vanessa Garcia Larsen, Karl Franklin, Debbie Jarvis, Pascal Demoly, Jennifer L Perret, Judith Garcia Aymerich, Sandra Dorado Arenas, Joachim Heinrich, Kjell Toren, Rain Jogi, Christer Janson

BMJ Open | BMJ PUBLISHING GROUP | Published : 2020

Abstract

OBJECTIVES: To compare the prevalence of different insomnia subtypes among middle-aged adults from Europe and Australia and to explore the cross-sectional relationship between insomnia subtypes, respiratory symptoms and lung function. DESIGN: Cross-sectional population-based, multicentre cohort study. SETTING: 23 centres in 10 European countries and Australia. METHODS: We included 5800 participants in the third follow-up of the European Community Respiratory Health Survey III (ECRHS III) who answered three questions on insomnia symptoms: difficulties falling asleep (initial insomnia), waking up often during the night (middle insomnia) and waking up early in the morning and not being able to ..

View full abstract

Grants

Awarded by Belgium: Antwerp South, Antwerp City: Research Foundation Flanders (FWO)


Awarded by Estonia: Estonian Ministry of Education


Awarded by Germany: Erfurt: German Research Foundation


Awarded by Germany: Hamburg: German Research Foundation


Awarded by Icelandic Research found


Awarded by Norway: Norwegian Research council


Awarded by Norway: Western Norway Regional Health Authorities


Awarded by Spain: Fondo de Investigacion Sanitaria


Awarded by Spain: Sociedad Espanola de Neumologia y Cirurgia Toracica


Awarded by Sweden: Fondo de Investigacion Sanitaria


Awarded by Barcelona: Fondo de Investigacion Sanitaria


Awarded by Galdakao: Fondo de Investigacion Sanitaria


Awarded by Huelva: Fondo de Investigacion Sanitaria


Awarded by Servicio Andaluz de Salud Oviedo: Fondo de Investigacion Sanitaria


Awarded by Switzerland: The Swiss National Science Foundation


Awarded by Switzerland: European Commission


Awarded by Switzerland: Wellcome Trust


Awarded by UK: Medical Research Council


Funding Acknowledgements

Financial support for ECRHS III: Australia: National Health & Medical Research Council. Belgium: Antwerp South, Antwerp City: Research Foundation Flanders (FWO), grant code G.0.410.08.N.10 (both sites). Estonia: TartuSF0180060s09 from the Estonian Ministry of Education. France: (all) Ministere de la Sante. Programme Hospitalier de Recherche Clinique (PHRC) national 2010. Bordeaux: INSERM U897 Universite Bordeaux segalen; Grenoble: Comite Scientifique AGIRadom 2011; Paris: Agence Nationale de la Sante, Region Ile de France, domaine d'interet majeur (DIM). Germany: Erfurt: German Research Foundation HE 3294/10-1; Hamburg: German Research Foundation MA 711/6-1, NO 262/7-1. Iceland: Reykjavik: The Landspitali University Hospital Research Fund, University of Iceland Research Fund, ResMed Foundation, California, USA, Orkuveita Reykjavikur (Geothermal plant), Vegageroin (The Icelandic Road Administration (ICERA). The Icelandic Research found -grant no 1 73 701-052. Italy: all Italian centres were funded by the Italian Ministry of Health, Chiesi Farmaceutici SpA, in addition Verona was funded by Cariverona foundation, Education Ministry (MIUR). Norway: Norwegian Research council grant no 214123, Western Norway Regional Health Authorities grant no 911631, Bergen Medical Research Foundation. Spain: Fondo de Investigacion Sanitaria (PS09/02457, PS09/00716 09/01511) PS09/02185 PS09/03190), Servicio Andaluz de Salud, Sociedad Espanola de Neumologia y Cirurgia Toracica (SEPAR 1001/2010). Sweden: all centres were funded by The Swedish Heart and Lung Foundation, The Swedish Asthma and Allergy Association, The Swedish Association against Lung and Heart Disease. Fondo de Investigacion Sanitaria (PS09/02457); Barcelona: Fondo de Investigacion Sanitaria (FIS PS09/00716); Galdakao: Fondo de Investigacion Sanitaria (FIS 09/01511); Huelva: Fondo de Investigacion Sanitaria (FIS PS09/02185); and Servicio Andaluz de Salud Oviedo: Fondo de Investigacion Sanitaria (FIS PS09/03190). Sweden: all centres were funded by The Swedish Heart and Lung Foundation, The Swedish Asthma and Allergy Association, The Swedish Association against Lung and Heart Disease. Swedish Research Council for health, working life and welfare (FORTE); Goteborg also received further funding from the Swedish Council for Working life and Social Research. Umea also received funding from Vasterbotten Country Council ALF grant. Switzerland: The Swiss National Science Foundation (grants no 33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532 and 4026-028099), The Federal Office for Forest, Environment and Landscape, The Federal Office of Public Health, The Federal Office of Roads and Transport, the Canton's Government of Aargan, Basel--Stadt, Basel--Land, Geneva, Luzern, Ticino, Valais and Zurich, the Swiss Lung League, The Canton's Lung League of Basel Stadt/Basel, Landschaft, Geneva, Ticino, Valais and Zurich, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics, European Commission 018996 (GABRIEL), Wellcome Trust WT 084703MA, UK: Medical Research Council (Grant Number 92091). Support also provided by the National Institute for Health Research through the Primary Care Research Network.